Moderna (NASDAQ:MRNA) Upgraded to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Moderna (NASDAQ:MRNA) from a hold rating to a buy rating in a research report report published on Saturday. The firm currently has $15.00 target price on the stock.
According to Zacks, “Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company’s product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States. “
MRNA has been the subject of several other research reports. Chardan Capital restated a buy rating and set a $40.00 target price on shares of Moderna in a research note on Sunday, June 2nd. Piper Jaffray Companies increased their target price on Moderna from $24.00 to $30.00 and gave the company an overweight rating in a research note on Wednesday, May 8th. Finally, Oppenheimer increased their target price on Moderna from $27.00 to $31.00 and gave the company an outperform rating in a research note on Wednesday, May 29th. Ten research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus target price of $26.30.
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
See Also: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.